肝纤维化基础和临床研究热点问题

doi:10.3969/j.issn.1672-5069.2016.01.001

Abstract

Lu Lungen. Highlight in hepatic fibrosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 1-3.

[1] Marcellin P,Gane E,Buti M,et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study. Lancet,2012,11:1-8.
[2] Duval F,Moreno-Cuevas JE,González-Garza MT,et al. Liver fibrosis and mechanisms of the protective action of medicinal plants targeting inflammation and the immune response. Int J Inflam,2015,2015:943497.
[3] Duval F,Moreno-Cuevas JE,González-Garza MT,et al. Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis. Chin Med,2014,9（1）:27.
[4] Xu R,Zhang Z,Wang FS. Liver fibrosis:mechanisms of immune-mediated liver injury. Cell Mol Immunol. 2012,9（4）:296-301.
[5] Trautwein C,Friedman SL,Schuppan D,et al. Hepatic fibrosis: Concept to treatment. J Hepatol,2015,62（1 Suppl）:S15-24.
[6] Boursier J,Louvet A. Liver fibrogenesis and genetic factors. Clin Res Hepatol Gastroenterol,2011,35:3-9.
[7] Ramezani A,Banifazl M,Mamishi S. The influence of human leukocyte antigen and IL-10 gene polymorphisms on hepatitis B virus outcome. Hepat Mon,2012,12:320-325.
[8] Andres DR,Jose TA,Jordan JF. Nonivasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Ann Hepatol,2012,11:426-439.
[9] Germani G,Hytiroglou P,Fotiadu A,et al. Assessment of fibrosis and cirrhosis in liver biopsies:an update. Semin Liver Dis,2011,31:82-90.
[10] Zeng MD,Lu LG,Mao YM,et al. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology,2005,42:1437-1445.
[11] Jin W,Lin Z. Diagnostic accuracy of the asparrate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis:a leading meta-analysis. BMC Gastroenterol,2012,12:14.
[12] Castara L,Sebastiani G,Le Bail B,et a1．Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C．J Hepatol,2010,52:191-198．
[13] Zandieh A,Payabvash S,Pasalar P,et al. Gadolinium chloride, a Kupffer cell inhibitor,attenuates hepatic injury in a rat model of chronic cholestasis. Hum Exp Toxicol,2011,30:1804-1810.

[1]	. Consensus on the diagnosis and therapy of hepatic fibrosis [J]. Journal of Practical Hepatology, 2019, 22(6): 793-803.
[2]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[3]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[4]	Wu Yaping, Zhou Bingqing, Jiang Peili. Risk factors of severe hepatic fibrosis in patients with chronic hepatitis C with previous paid blood donation [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 196-199.
[5]	Liu Enqiang, Chen Guo, Liao Xiuyong, et al.. Inhibition of TGF-β1/Smad/ERK passway by astaxanthin in rats with CCl₄-induced liver fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 842-846.
[6]	Pan Gaofeng, Fu Maoying, Gao Yufeng.. Endoplasmic reticulum stress in pathogenesis of hepatic fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 987-990.
[7]	Zhu Chuanlong，Zhu Tiantian，Wang Kung，et al.. Serum Pygo2 levels as an indicator of liver fibrosis in patients with chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 161-164.
[8]	Hu Ye, Zhang Guo.. Diagnosis, severity assessment of hepatic fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 13-16.
[9]	Zhang Jianqiong，Xu Liang，Li Ping，et al.. Diagnostic efficacy of FibroScan and three diagnostic models in diagnosis of liver fibrosis in chronic hepatitis B patients with mild hepatic steatosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(6): 663-668.
[10]	Cai Lebin, Tao Na.. Efficacy of pegylated interferon α-2a combined with adefovir dipivoxil and their effects on serum T lymphocyte cytokines and hepatic fibrosis indexes in patients with HBeAg-positive chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 532-535.
[11]	Qian Peiguo, Lian Xiaoxiao, Guo Xiaoxia.. Application of noninvasive diagnostic model in diagnosis of liver fibrosis in patients with hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 578-582.
[12]	Tong Yanyan, Li Guangming, Deng Yilin, et al. Inhibition of primary cultured hepatic stellate cell activation by phenylarsine oxide in vitro [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(4): 413-417.
[13]	Zhao Yuqian, Xu Xingmei, Yang Huijuan, et al. Clinical observation of entecavir combined with Liuweiwuling tablets in treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 83-85.
[14]	Huang Hong，Kang Yi，Huang Xuping，et al.. Effect of malotilate on expression of Smads protein in rats with dimenthylnitrosamine-induced hepatic fibrosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 525-529.
[15]	Tan Pufang，Nan Yuemin，Wang Rongqi，et al.. Impact of Fuzheng Huayu recipe on the expression of angiogenic growth factor in mice with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(4): 352-355.

Highlight in hepatic fibrosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments